当前位置:首页>产品中心>单抗/多抗>Anti-Human CD104/ITGB4 Polyclonal Antibody|抗人CD104/ITGB4多克隆抗体(靶标:人整合素β4亚基/CD104)

Anti-Human CD104/ITGB4 Polyclonal Antibody|抗人CD104/ITGB4多克隆抗体(靶标:人整合素β4亚基/CD104)

  • 货号:RB9THB684014
  • 价格:面议
  • 点击:575

产品介绍

产品参数

形态Liquid
宿主种属Rabbit
克隆性Polyclonal
抗体亚型IgG
纯化方式Purified by antigen affinity column.
内毒素水平Please contact with the lab for this information.
应用ELISA, IHC, WB
种属反应性Human
靶标CD104, GP150, ITGB4, Integrin beta-4
免疫原E. coli - derived recombinant Human CD104/ITGB4 (Leu923-Cys1197).
储存缓冲液0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
产品使用说明ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000
登录号P16144
背景信息

Integrin beta-4 (CD104/ITGB4) is a ~202 kDa protein. Integrin alpha-6/beta-4 is a receptor for laminin. Plays a critical structural role in the hemidesmosome of epithelial cells. Is required for the regulation of keratinocyte polarity and motility. ITGA6:ITGB4 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling. ITGA6:ITGB4 binds to IGF1 and this binding is essential for IGF1 signaling.

1. Ieguchi, K. et al. (2010) The Journal of biological chemistry 285, 31388-98. PMID: 20682778
2. Fujita, M. et al. (2012) The Journal of biological chemistry 287, 12491-500. PMID: 22351760
3. Cedano Prieto, DM. et al. (2017) PloS one 12, e0184285. PMID: 28873464
备注For research use only
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 564
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 367
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 570
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 318
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 446
Anti-Infliximab Non-Neutralizing Recombinant Antibody |抗英夫利昔单抗非中和重组抗体(靶标:英夫利昔单抗非中和抗体) 599
Anti-Infliximab Non-Neutralizing Recombinant Antibody |抗英夫利昔单抗非中和重组抗体(靶标:英夫利昔单抗非中和抗体) 538
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 645
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 497
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 298
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 445
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 338
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 577
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 503
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 470
Anti-Elotuzumab Non-Neutralizing Recombinant Antibody|抗埃罗妥珠单抗非中和重组抗体(靶标:埃罗妥珠单抗非中和抗体) 615
Anti-Elotuzumab Neutralizing Recombinant Antibody |抗埃罗妥珠单抗中和重组抗体(靶标:埃罗妥珠单抗中和抗体) 281
Anti-Elotuzumab Neutralizing Recombinant Antibody |抗埃罗妥珠单抗中和重组抗体(靶标:埃罗妥珠单抗中和抗体) 354
Anti-Oleclumab Neutralizing Recombinant Antibody |抗奥乐克单抗中和重组抗体(靶标:奥乐克单抗中和抗体) 338
Anti-Oleclumab Neutralizing Recombinant Antibody |抗奥乐克单抗中和重组抗体(靶标:奥乐克单抗中和抗体) 347
总计 33037 个记录,共 1652 页,当前第 1649 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00